What did Novo Nordisk's CEO announce regarding Wegovy pill's regulatory pathway in China?

Novo Nordisk's CEO Mike Doustdar announced that the company plans to seek Chinese regulatory approval for its Wegovy pill 'very soon', as stated in the news body.

How does Novo Nordisk's Wegovy pill compare to Eli Lilly's orforglipron in terms of development status for the Chinese market?

While Eli Lilly submitted a marketing application for its oral GLP-1 agonist orforglipron to China's drug regulator at the end of 2025, Novo Nordisk has not yet submitted but plans to seek approval for its Wegovy pill 'very soon', indicating it is currently behind Lilly in the regulatory process for China.

Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO

Jun 15, 2026

Novo Nordisk plans to seek Chinese regulatory approval for its oral Wegovy pill very soon, CEO Mike Doustdar said. The company aims to compete with Eli Lilly in China's rapidly expanding GLP-1 market, where sales reached $207 million in Q1.

reuters

2026-02-25

Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs

2026-04-13

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

2026-04-23

Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study

2026-05-05

Novo Nordisk's first-quarter profit beats forecasts

2026-05-26

Global Firms Bring More Work In-House at India Hubs on AI Boost